HPLC Impurity Thresholds for 3-Methyl-6-nitroindazole in Pazopanib Synthesis
HPLC Impurity Thresholds and COA Specifications for 3-Methyl-6-nitroindazole in Pazopanib Synthesis
In the manufacturing process of pazopanib, a kinase inhibitor precursor, the purity of the indazole derivative 3-methyl-6-nitroindazole (CAS 6494-19-5) is a critical quality attribute. As a procurement manager, understanding the HPLC impurity thresholds and certificate of analysis (COA) specifications is essential to ensure batch-to-batch consistency and regulatory compliance. This compound, also referred to as 3-Methyl-6-nitro-1H-indazole or 6-Nitro-3-methylindazole, serves as a key intermediate in the synthesis route. At NINGBO INNO PHARMCHEM CO.,LTD., we position our product as a drop-in replacement for existing sources, offering identical technical parameters with enhanced cost-efficiency and supply chain reliability.
Our standard COA for 3-methyl-6-nitroindazole specifies a purity of ≥99.0% by HPLC, with individual impurity thresholds strictly controlled. The primary related substances monitored include 6-nitroindazole and positional isomers such as 3-methylindazole. These limits are derived from extensive process development and field experience. For instance, we have observed that trace levels of 6-nitroindazole above 0.15% can lead to oxidative discoloration during the final coupling stages of pazopanib synthesis, a non-standard parameter that is often overlooked in generic specifications. This hands-on knowledge ensures that our product consistently meets the stringent requirements of pharmaceutical manufacturing.
When evaluating a global manufacturer, it is crucial to review the COA for parameters such as assay, water content, residual solvents, and heavy metals. Our technical support team provides detailed documentation, including batch-specific COAs, to facilitate your quality assurance process. For a deeper understanding of how physical properties impact downstream processing, refer to our article on optimizing particle size distribution for 3-methyl-6-nitroindazole filtration, which discusses how PSD affects filtration efficiency and yield.
Quantifying Critical Related Substances: 6-Nitroindazole and 3-Methylindazole Isomers Below 0.15%
The synthesis of 3-methyl-6-nitroindazole, as described in patent CN103319410A, involves the methylation of 6-nitroindazole. This reaction can produce by-products such as unreacted 6-nitroindazole and regioisomeric 3-methylindazole derivatives. In our industrial purity standards, we set the acceptance criterion for any single unknown impurity at ≤0.10% and total impurities at ≤1.0%. However, for the critical related substances 6-nitroindazole and 3-methylindazole isomers, we enforce a tighter limit of ≤0.15% each. This is based on our field experience that these impurities, even at low levels, can act as chain terminators or cause unwanted side reactions in the subsequent steps of pazopanib synthesis.
To achieve these thresholds, our manufacturing process employs advanced purification techniques, including recrystallization and column chromatography, monitored by a validated HPLC method. The HPLC method uses a C18 column with a mobile phase of acetonitrile and phosphate buffer, detecting at 254 nm. This method is capable of separating and quantifying all potential impurities, ensuring that the 3-methyl-6-nitroindazole meets the stringent requirements for use as a pharmaceutical intermediate. For procurement managers, it is advisable to request a typical HPLC chromatogram from the supplier to verify the impurity profile. Additionally, understanding the thermal stability of the product is crucial; our article on mitigating thermal degradation in bulk 3-methyl-6-nitroindazole storage provides insights into preserving purity during transport and warehousing.
Impact of Trace Impurities on Oxidative Discoloration During Final Coupling Stages
One non-standard parameter that we have extensively characterized is the propensity of 3-methyl-6-nitroindazole to undergo oxidative discoloration when trace impurities are present. In the final coupling stage of pazopanib synthesis, the indazole intermediate is reacted with a sulfonamide derivative. We have observed that if the 6-nitroindazole content exceeds 0.15%, the reaction mixture develops a yellow to brown coloration, which can persist in the final API. This discoloration is not merely aesthetic; it indicates the formation of oxidative by-products that can affect the purity and yield of pazopanib. Our quality assurance protocols include a dedicated test for color stability under accelerated conditions, ensuring that each batch maintains a white to off-white appearance.
This field knowledge is critical for procurement managers who are sourcing 3-methyl-6-nitroindazole for large-scale manufacturing. By selecting a supplier that understands these edge-case behaviors, you can avoid costly batch rejections and rework. Our technical support team can provide guidance on handling and storage conditions to minimize the risk of discoloration. For example, we recommend storing the product under nitrogen atmosphere at controlled room temperature, away from light and moisture. These precautions are part of our commitment to delivering a high-quality indazole derivative that performs consistently in your synthesis route.
Batch Acceptance Criteria and GMP Manufacturing Compliance for Bulk 3-Methyl-6-nitroindazole
For industrial procurement, batch acceptance criteria extend beyond HPLC purity. Our manufacturing process is conducted under strict quality control, with in-process checks at critical stages. The following table summarizes the key technical parameters and acceptance limits for our 3-methyl-6-nitroindazole:
| Parameter | Specification | Test Method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual |
| Assay (HPLC) | ≥99.0% | In-house HPLC method |
| 6-Nitroindazole | ≤0.15% | HPLC |
| 3-Methylindazole Isomer | ≤0.15% | HPLC |
| Any Single Unknown Impurity | ≤0.10% | HPLC |
| Total Impurities | ≤1.0% | HPLC |
| Water Content (KF) | ≤0.5% | Karl Fischer |
| Residual Solvents | Meets ICH Q3C limits | GC |
| Heavy Metals | ≤20 ppm | ICP-MS |
While we do not claim EU REACH compliance, our product is manufactured in accordance with GMP principles, and we provide full documentation to support your regulatory submissions. The batch-specific COA includes all test results, and we retain samples for at least three years for retrospective analysis. For procurement managers, this level of transparency is essential for supplier qualification and audit readiness. Our 3-methyl-6-nitroindazole product page offers additional details on packaging and ordering information.
Bulk Packaging and Supply Chain Considerations for Industrial-Scale Procurement
For bulk orders, we offer standard packaging in 25 kg fiber drums with double PE liners, or 210L steel drums for larger quantities. For high-volume procurement, IBC totes can be arranged. Our logistics team ensures secure and compliant transportation, focusing on physical packaging integrity to prevent contamination and moisture ingress. We maintain safety stock levels to support just-in-time delivery, reducing your inventory carrying costs. As a global manufacturer, we have established reliable shipping routes to major pharmaceutical hubs, with typical lead times of 4-6 weeks for custom orders.
When sourcing 3-methyl-6-nitroindazole, consider the total cost of ownership, including purity, packaging, and technical support. Our drop-in replacement strategy means you can switch to our product without modifying your existing synthesis protocols, provided the COA matches your specifications. We encourage you to request a sample for evaluation and compare it against your current supplier's material. Our technical sales team is available to discuss your specific impurity profiling requirements and provide a competitive bulk price quote.
Frequently Asked Questions
What is the typical batch-to-batch assay variance for 3-methyl-6-nitroindazole?
Our manufacturing process demonstrates excellent reproducibility, with batch-to-batch assay variance typically within ±0.3% as determined by HPLC. We employ statistical process control to monitor critical parameters, and each batch is tested against the same acceptance criteria. The COA for each batch provides the exact assay value, ensuring transparency for your quality assurance team.
How can I verify the impurity profile using a third-party lab?
We welcome third-party verification. You can send a sample from any batch to an independent laboratory for analysis. We provide a reference standard and our validated HPLC method upon request to facilitate method transfer. This allows you to confirm that the impurity levels, particularly for 6-nitroindazole and 3-methylindazole isomers, are within the specified limits. Our technical support team can assist with any questions regarding the analytical procedure.
What impurity profiling requirements are needed for regulatory submission dossiers?
For regulatory submissions, you will need to provide a detailed impurity profile, including identification, quantification, and limits for all potential impurities. Our COA includes data on specified impurities, unspecified impurities, and total impurities. We can also supply a declaration of the synthetic route and potential carryover impurities. While we do not handle regulatory filings directly, our documentation is designed to support your Drug Master File (DMF) or equivalent submission. Please refer to the batch-specific COA for the most accurate data.
Sourcing and Technical Support
In summary, the HPLC impurity thresholds for 3-methyl-6-nitroindazole are critical to the success of pazopanib synthesis. By partnering with a supplier that understands the nuances of impurity control, oxidative stability, and GMP compliance, you can ensure a robust supply chain for your pharmaceutical manufacturing. Our product is designed as a seamless drop-in replacement, offering identical performance with added value through technical expertise and reliable logistics. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.